Xencor, Inc. (NasdaqGM: XNCR)
Health Care · Biotechnology · US
$24.50
-1.37% today · +111.0% 1Y
Xencor, Inc. (NasdaqGM: XNCR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.85B and employs 260 people.
Over the last twelve months the share price has gained 111.0%, trading between 10.38 and 30.61.
Tweenvest scores Xencor, Inc. across four factors: quality 42/100, value 50/100, growth 23/100. Its strongest factor is value.
XNCR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.85B
- Revenue (TTM)
- $104.97M
- P/E
- —
- EPS
- -2.18
- Dividend yield
- —
- Beta (5Y)
- 0.88
- 52-week high
- $30.61
- 52-week low
- $10.38
- Avg volume (3M)
- —
- Shares outstanding
- 74.35M
- Employees
- 260
- Next earnings
- —
About Xencor, Inc.
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
- ISIN
- US98401F1057
- Founded
- 1997
- Listed since
- Dec 3, 2013
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Chengdu Olymvax Biopharmaceuticals Inc.SHSE: 688319 | $1.88B | CN¥31.18 | -1.08% |
| Zymeworks Inc.NasdaqGS: ZYME | $1.88B | $25.26 | -4.79% |
| Novavax, Inc.NasdaqGS: NVAX | $1.85B | $11.01 | -1.87% |
| Sarepta Therapeutics, Inc.NasdaqGS: SRPT | $1.85B | $18.21 | +4.06% |
| Zenas BioPharma, Inc.NasdaqGS: ZBIO | $1.84B | $26.24 | -7.26% |
| Mesoblast LimitedASX: MSB | $1.84B | AU$2.04 | -5.56% |
| Pell Bio-Med Technology Co., Ltd.TWSE: 6949 | $1.83B | NT$44.50 | -11.53% |
| Biohaven Ltd.NYSE: BHVN | $1.79B | $11.93 | +0.42% |
Figures last refreshed Oct 4, 2026.